Please assess the completion status of the following clinical trial:

Trial Title: Memantine for Prevention of Cognitive Decline in Patients With Breast Cancer

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Able to provide informed consent~* At least 18 years of age~* Able to speak English~* Diagnosed with breast cancer, Stages I-III~* Scheduled for adjuvant or neoadjuvant chemotherapy~Exclusion Criteria:~* A history of adverse reaction to memantine~* Another cancer diagnosis with an estimated survival of less than five years~* Previous chemotherapy exposure~* Severe cognitive impairment, defined as Blessed Orientation Memory Concentration Test (BOMC) ≥ 11.~* Pregnancy, confirmed by a negative pregnancy test within 30 days of study enrollment, or breastfeeding~* Current alcohol or drug abuse

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Memantine (Type: EXPERIMENTAL): Subjects receive memantin

Based on this trial design, predict the completion outcome and termination type (if applicable).